These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33686772)

  • 21. A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours.
    Li X; Qiu M; Wang S; Zhu H; Feng B; Zheng L
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):593-604. PubMed ID: 32008115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Ameratunga M; Braña I; Bono P; Postel-Vinay S; Plummer R; Aspegren J; Korjamo T; Snapir A; de Bono JS
    Br J Cancer; 2020 Dec; 123(12):1730-1736. PubMed ID: 32989226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.
    Kondo S; Tajimi M; Funai T; Inoue K; Asou H; Ranka VK; Wacheck V; Doi T
    Invest New Drugs; 2020 Dec; 38(6):1836-1845. PubMed ID: 32578154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.
    Awada A; Eskens FA; Piccart M; Cutler DL; van der Gaast A; Bleiberg H; Wanders J; Faber MN; Statkevich P; Fumoleau P; Verweij J;
    Eur J Cancer; 2002 Nov; 38(17):2272-8. PubMed ID: 12441264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
    Chuk MK; Widemann BC; Minard CG; Liu X; Kim A; Bernhardt MB; Kudgus RA; Reid JM; Voss SD; Blaney S; Fox E; Weigel BJ
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27077. PubMed ID: 29693796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.
    Schöffski P; Aftimos P; Dumez H; Deleporte A; De Block K; Costermans J; Billiet M; Meeus MA; Lee C; Schnell D; Goeldner RG; Awada A
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):99-108. PubMed ID: 26650227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
    Gore L; Rothenberg ML; O'Bryant CL; Schultz MK; Sandler AB; Coffin D; McCoy C; Schott A; Scholz C; Eckhardt SG
    Clin Cancer Res; 2008 Jul; 14(14):4517-25. PubMed ID: 18579665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
    Piha-Paul SA; Sachdev JC; Barve M; LoRusso P; Szmulewitz R; Patel SP; Lara PN; Chen X; Hu B; Freise KJ; Modi D; Sood A; Hutti JE; Wolff J; O'Neil BH
    Clin Cancer Res; 2019 Nov; 25(21):6309-6319. PubMed ID: 31420359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
    Langenberg MH; Witteveen PO; Roodhart JM; Verheul HM; Mergui-Roelvink M; van der Sar J; Brendel E; Laferriere N; Schellens JH; Voest EE
    Clin Cancer Res; 2010 Apr; 16(7):2187-97. PubMed ID: 20233884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.
    Saleh MN; Patel MR; Bauer TM; Goel S; Falchook GS; Shapiro GI; Chung KY; Infante JR; Conry RM; Rabinowits G; Hong DS; Wang JS; Steidl U; Naik G; Guerlavais V; Vukovic V; Annis DA; Aivado M; Meric-Bernstam F
    Clin Cancer Res; 2021 Oct; 27(19):5236-5247. PubMed ID: 34301750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
    de Weger VA; de Jonge M; Langenberg MHG; Schellens JHM; Lolkema M; Varga A; Demers B; Thomas K; Hsu K; Tuffal G; Goodstal S; Macé S; Deutsch E
    Br J Cancer; 2019 Feb; 120(3):286-293. PubMed ID: 30585255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
    Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
    Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study.
    Kondo S; Katsuya Y; Yonemori K; Komuro K; Sugeno M; Kawata T; Ghiorghiu D; Meulendijks D; Yamamoto N
    Cancer Treat Res Commun; 2024; 39():100809. PubMed ID: 38593512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study.
    Ono A; Murakami H; Seto T; Shimizu T; Watanabe S; Takeshita S; Takeda K; Toyoshima J; Nagase I; Bahceci E; Morishita M; Morita S; Fukuoka M; Nakagawa K
    Drugs R D; 2021 Mar; 21(1):65-78. PubMed ID: 33331996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.
    Fujisaka Y; Yamada Y; Yamamoto N; Shimizu T; Fujiwara Y; Yamada K; Tamura T; Watanabe H; Sun YN; Bass MB; Seki M
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):935-43. PubMed ID: 20107802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.
    Shimizu T; Fukuoka K; Takeda M; Iwasa T; Yoshida T; Horobin J; Keegan M; Vaickus L; Chavan A; Padval M; Nakagawa K
    Cancer Chemother Pharmacol; 2016 May; 77(5):997-1003. PubMed ID: 27025608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.
    Erba HP; Becker PS; Shami PJ; Grunwald MR; Flesher DL; Zhu M; Rasmussen E; Henary HA; Anderson AA; Wang ES
    Blood Adv; 2019 Jul; 3(13):1939-1949. PubMed ID: 31253596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.